

**Amendments to the claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application.

**Listing of claims:**

Claims 1-26 (canceled).

27 (previously presented): A compound comprising a structural entity which binds or inhibits secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it, wherein the compound

a) blocks and/or neutralizes at least one function of the sPLA2 IIA, on a cell surface or in a solution, and/or

b) depletes sPLA2 IIA from a solution.

28 (previously presented): The compound of claim 27 wherein the sPLA2 IIA is human sPLA2 IIA and the compound blocks and/or neutralizes the at least one function of the sPLA2 IIA in a body fluid or tissue.

29 (previously presented): The compound according to claim 27 being a polypeptide and the structural entity being a binding site to sPLA2 IIA.

- 30 (previously presented): The compound according to claim 27 being an antibody and the structural entity being an antigen-binding site to sPLA2 IIA.
- 31 (previously presented): The compound according to claim 30, wherein the antibody is a monoclonal antibody.
- 32 (previously presented): The compound according to claim 31, wherein the monoclonal antibody is obtainable by immunizing a vertebrate.
- 33 (previously presented): The compound according to claim 31, wherein the monoclonal antibody is obtainable by immunizing a transgenic vertebrate.
- 34 (previously presented): The compound according to claim 31, wherein the monoclonal antibody is obtainable by immunizing a humanized (with a humanized immune system) vertebrate.
- 35 (currently amended): The compound according to claim ~~27~~ 31, wherein the monoclonal antibody is obtainable by immunizing an immune defective mouse repopulated with vital immune cells.
- 36 (previously presented): The compound according to claim 30, wherein the antibody is a recombinant antibody.

37 (previously presented): The compound according to claim 36, wherein the antibody is a humanized or human antibody.

38 (previously presented): A host cell producing the compound according to claim 36.

39 (previously presented): A recombinant vector comprising a nucleotide sequence encoding the compound according to claim 36, operably linked to a regulating sequence capable of expressing the antibody in a host cell.

40 (previously presented): A secretory protein comprising the compound according to claim 36.

41 (previously presented): A host cell containing the vector according to claim 39.

42 (previously presented): A prokaryotic or eukaryotic cell line producing the recombinant antibody according to claim 36.

43 (previously presented): A non-human eukaryotic organism producing the recombinant compound according to claim 36.

44 (currently amended): A method of producing a recombinant molecule capable of binding sPLA2 IIA, comprising the steps of culturing the host cell of claim ~~42~~ 38 to produce the compound and isolating the produced compound.

45 (previously presented): A method of using the compound of claim 27 comprising administering a therapeutically effective amount of the compound to a patient having an increased IL-6, CRP, and/or sPLA2 level to inhibit an immunologic, inflammatory, and/or pathophysiological response.

46 (previously presented): A pharmaceutical composition for reducing the sPLA2 IIA concentration and/or blocking, neutralizing sPLA2 IIA, containing a therapeutically effective amount of the compound according to claim 27 and a pharmaceutically acceptable carrier.

47 (previously presented): A method of treatment for reducing inflammatory immune and/or pathophysiological responses, the method comprising reducing the sPLA2 IIA concentration and/or neutralizing sPLA2 IIA by administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

48 (currently amended): A method of treatment for reducing cell and/or ~~endothelial~~ endothelial injury and/or destruction, the method comprising reducing the sPLA2 IIA concentration

and/or neutralizing sPLA2 IIA by administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

49 (previously presented): A method of treatment for reducing acute endothelial injury and/or destruction associated with stroke, cardiac infarction, avoidance of sudden cardiac death, burnt offering, for severe surgery or other injury with severe wound areas, diabetic shock, acute liver failure, pancreatitis, neurodegenerative diseases, or irradiation-induced leukemia, the method comprising reducing the sPLA2 IIA concentration and/or neutralizing sPLA2 IIA by administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

50 (currently amended): A method of treatment for reducing long term endothelial injury and/or destruction associated with medium CRP-amounts, atherosclerosis, unstable angina, diabetes type I or type II, ~~overweigt~~ overweight and/or obesity, ~~alcoholim~~ alcoholism, Hormone Replacement Therapy (HRT), old age, or smoking, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

51 (previously presented): A method of treatment for preventing allograft transplant rejection or xeno-transplant rejection, the method comprising administering to a patient in need of the

treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

52 (previously presented): A method of treatment for induction of allo-transplant or xeno-transplant tolerance or inhibition of T cell activation, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

53 (previously presented): A method of treatment or prevention of an autoimmune disease, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

54 (currently amended): A method of treatment or prevention of an autoimmune disease selected from the group consisting of SLE, osteo arthritis, rheumatoid ~~arthritis~~ arthritis, multiple sclerosis, myasthenia gravis, Graves' disease, psoriasis vulgaris, dilated cardiomyopathy, diabetes mellitus, Bechterew, inflammatory bile disease, ulcerative colitis, Crohn's disease, idiopathic thrombocytopenia purpura (ITP), aplastic anemia, idiopathic dilated cardiomyopathy (IDM), autoimmune thyroiditis, Goodpastures' disease, and arterial and venous chronic inflammation, the method comprising administering to a patient in need of

the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

55 (previously presented): A method of treatment of an HIV-infected patient, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of the pharmaceutical composition according to claim 46.

56 (previously presented): A medicament useful to inhibit an immunologic, inflammatory, and/or pathophysiological response comprising the compound of claim 27 in combination with an additional therapeutically active agent.

57 (previously presented): The medicament of claim 56 wherein the additional therapeutically active agent is an anti-inflammatory substance.

58 (previously presented): The medicament of claim 56 wherein the additional therapeutically active agent is selected from the group consisting of an anti-IL-6-molecule, anti-IL-1 $\beta$ -molecule, anti-CRP-molecule, complement blocker, and a combination thereof.